Filtered By:
Condition: Diabetes Type 2
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 31 results found since Jan 2013.
COVID-19 Can Cause New Cholesterol Problems. What to Know
Not long after the start of the global coronavirus pandemic, it was apparent that many people infected with SARS-CoV-2 were developing persistent and, in some cases, debilitating health problems. Now known widely as post-Covid syndrome or Long COVID, the most common symptoms of this condition are fatigue, attention problems, headaches, muscle or joint pain, and weakness. But those are just the start. Medical researchers have also linked SARS-CoV-2 to lingering complications in multiple organs and systems, and some recent work has found that new-onset cholesterol problems may be an under-recognized but common complication o...
Source: TIME: Health - May 30, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis
CONCLUSION: Careful monitoring of severe AEs in patients with T2DM may be necessary, especially for those related to thrombotic events and neurological dysfunctions after COVID-19 vaccination.PMID:36872064 | DOI:10.4093/dmj.2022.0129
Source: Diabetes and Metabolism Journal - March 5, 2023 Category: Endocrinology Authors: Hye Jun Kim Sang Jun Lee Soonok Sa Jung Ho Bae Gyuseon Song Chae Won Lee Ju Hee Kim Sung Ryul Shim Myunghee Hong Hyun Wook Han Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
